SCHEMBL952368

SCHEMBL952368

c1ccc(CCN2CCNCC2OCc2ccccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.48
MITF O75030 1/20 0.46
SIGMAR1 Q99720 1/20 0.43
HRH3 Q9Y5N1 3/20 0.41
GBA1 P04062 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
SLC6A3 Q01959 3/20 0.40
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
GAA P10253 1/20 0.39
HTR1A P08908 1/20 0.39
HTR2A P28223 1/20 0.38
HTR3A P46098 1/20 0.38
IDE P14735 1/20 0.38
UBE2N P61088 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28192205 0.78 CYP2C19 (0.44) CYP2C19SIGMAR1SLC6A3SLC6A2SLC6A4
SCHEMBL27638743 0.77 SIGMAR1 (0.50) MITFSIGMAR1HRH3SLC6A3SLC6A2
SCHEMBL28744475 0.76 CYP2C19 (0.43) CYP2C19SIGMAR1SLC6A3SLC6A2SLC6A4
SCHEMBL6642409 0.74 MITF (0.48) MITFSIGMAR1HRH3TDP1SLC6A3
SCHEMBL28078229 0.74 SIGMAR1 (0.49) MITFSIGMAR1HRH3GBA1SLC6A3
SCHEMBL4892854 0.73 GRM2 (0.50) MITFSIGMAR1GBA1SLC6A3SLC6A2
SCHEMBL7723235 0.71 CYP2C19 (0.49) CYP2C19SIGMAR1SLC6A3SLC6A2SLC6A4
Hydrochloric Acid SCHEMBL27476870 0.70 CYP2C19 (0.48) CYP2C19SIGMAR1SLC6A3SLC6A2SLC6A4
SCHEMBL8473445 0.69 TACR1 (0.46) CYP2C19SLC6A3SLC6A2SLC6A4HTR1A
SCHEMBL6619234 0.69 MITF (0.52) MITFSIGMAR1TDP1SLC6A3SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580821-B2 Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety HOFFMANN-LA ROCHE INC. (US) 2013-11-12 US disclosed
EP-1870396-B1 BENZYLOXYPROPYLAMINE DERIVATIVE NIPPON ZOKI PHARMACEUTICAL CO (JP) 2012-10-31 EP disclosed
EP-2004605-B1 PIPERIDINE DERIVATIVES USEFUL AS SEROTONIN TRANSPORTER INHIBITORS AND NEUROKININ-1 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2011-06-29 EP disclosed
US-7939552-B2 Tachykinin receptor anatgonist; good transfer into blood; long half-life; stability; bradycardial agents; antiinflammatory agents ; antallergens; analgesics; antiemetics; irritable bowel disorders; skin disorders; antidepressants; antiischemic agents ; anxiolytic agents; autoimmune diseases; muscle relax NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2011-05-10 US disclosed
US-20110105561-A1 SEROTONIN TRANSPORTER (SERT) INHIBITORS FOR THE TREATMENT OF DEPRESSION AND ANXIETY GRUNDSCHOBER CHRISTOPHE 2011-05-05 US disclosed
US-7872022-B2 Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety HOFFMANN-LA ROCHE INC. (US) 2011-01-18 US disclosed
EP-1957450-B1 SEROTONIN TRANSPORTER (SERT) INHIBITORS HOFFMANN LA ROCHE (CH) 2009-06-24 EP disclosed
EP-2004605-A1 PIPERIDINE DERIVATIVES USEFUL AS SEROTONIN TRANSPORTER INHIBITORS AND NEUROKININ-1 RECEPTOR ANTAGONISTS F. Hoffmann-Roche AG (CH) 2008-12-24 EP disclosed
US-20080262230-A1 Benzyloxypropylamine Derivative NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2008-10-23 US disclosed
EP-1957450-A1 SEROTONIN TRANSPORTER (SERT) INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2008-08-20 EP disclosed
EP-1870396-A1 BENZYLOXYPROPYLAMINE DERIVATIVE Nippon Zoki Pharmaceutical Co. Ltd. (JP) 2007-12-26 EP disclosed
WO-2007113153-A1 PIPERIDINE DERIVATIVES USEFUL AS SEROTONIN TRANSPORTER INHIBITORS AND NEUROKININ-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-10-11 WO disclosed
US-20070232652-A1 Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety HOFFMAN-LA ROCHE INC. 2007-10-04 US disclosed
WO-2007063009-A1 SEROTONIN TRANSPORTER (SERT) INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105561-A1 SEROTONIN TRANSPORTER (SERT) INHIBITORS FOR THE TREATMENT OF DEPRESSION AND ANXIETY SLC6A4, SLC6A1, SLC1A2 CYP2C19 409/4885MITF 2240/4885SIGMAR1 226/4885
US-20070232652-A1 Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety SLC6A4, SLC6A1, SLC1A2 CYP2C19 409/4885MITF 2240/4885SIGMAR1 226/4885
US-20080262230-A1 Benzyloxypropylamine Derivative BDKRB2, BDKRB1, PNMT CYP2C19 916/4885MITF 3068/4885SIGMAR1 657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.